Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04378777|
Recruitment Status : Enrolling by invitation
First Posted : May 7, 2020
Last Update Posted : July 14, 2020
|Condition or disease||Intervention/treatment|
|Coronavirus Disease 2019 (COVID-19) SARS-CoV-2||Procedure: Biological sample collection Procedure: Data Collection: Clinical Care Assessments|
This is a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with known or presumptive COVID-19. Detailed information will be collected regarding patient history and onset of illness upon enrollment. Participants will undergo longitudinal assessments of clinical status and pertinent clinical data (including clinical laboratory values, radiographic findings, medication use, oxygen and ventilatory support requirements, complications, etc.) will be recorded. In parallel, the study will conduct serial biologic sampling for detailed immunophenotyping to provide a comprehensive picture of immune changes that occur throughout the course of infection. The biologic samples to be collected for this observational study include blood, nasal swabs, and endotracheal aspirates.
Participants will be followed in hospital through Day 28, unless discharged earlier. If a participant requires an escalation to Intensive Care Unit (ICU)-level care, either within or outside of a dedicated ICU, additional samples will be collected within 24 and 96 hours of care escalation. Convalescent questionnaires and biologic samples will be collected at 3-month intervals up to Month 12 after infection symptom onset, if available. In addition, if a participant is discharged from the hospital prior to Day 28, attempts will be made to collect additional scheduled assessments through Day 28 on an outpatient basis, if feasible.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19 (DAIT-COVID-19-002)|
|Actual Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2021|
Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
Procedure: Biological sample collection
During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study [GWAS]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
Procedure: Data Collection: Clinical Care Assessments
Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
Other Name: Baseline data, clinical care assessments
- Mortality Rate Among COVID-19 Patients [ Time Frame: Day 1 to Day 28 ]The incidence of mortality in the first 28 days.
- Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]As a measure of disease acuity and severity.
- Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]As a measure of disease acuity and severity.
- Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]Ribonucleic acid (RNA) from the nasal swab will be used to assess SARS-CoV-2 viral load.
- Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12 [ Time Frame: Up to 12 Months ]Focus on the immune response to SARS-CoV-2, seroconversion and immunoglobulin and transitions. Antibody isotypes present in a patient specimen(s) provide information about the timing of initial exposure and may provide insight on the progression of the disease and prognosis.
- Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]Collected as part of clinical care.
- Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]Collected as part of clinical care.
- Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]A measure of disease morbidity.
- Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]A measure of disease morbidity.
- Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28 [ Time Frame: Day 1 to Day 28 ]A measure of disease morbidity.
- Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12 [ Time Frame: Up to 12 Months ]Method of immune profiling and quantitating the response to COVID-19 over time.
- Mechanistic: Gene Expression (Transcriptomics) in Blood [ Time Frame: Up to 12 Months ]To identify and quantitate differences in immune response associated with disease outcome.
- Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium [ Time Frame: Up to 12 Months ]To identify and quantitate differences in immune response associated with disease outcome.
- Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein [ Time Frame: Up to 12 Months ]To identify and quantitate differences in immune response associated with disease outcome.
- Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling [ Time Frame: Up to 12 Months ]To identify and quantitate differences in immune response associated with disease outcome.
- Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology [ Time Frame: Up to 12 Months ]Circulating immune biomarkers will be explored by use of the OLINK® (name of brand), a multiplex protein biomarker discovery panel.
Biospecimen Retention: Samples With DNA
- nasal secretion samples
- whole blood
- sputum secretions by endotracheal aspiration (for intubated patients)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04378777
|United States, Arizona|
|University of Arizona (UA) College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center|
|Tucson, Arizona, United States, 85724|
|United States, California|
|University of California, Los Angeles: Department of Medicine|
|Los Angeles, California, United States, 90024|
|University of California San Francisco School of Medicine|
|San Francisco, California, United States, 94115|
|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research|
|Stanford, California, United States, 94305|
|United States, Connecticut|
|Yale School of Medicine|
|New Haven, Connecticut, United States, 06520|
|United States, Georgia|
|Emory University School of Medicine|
|Atlanta, Georgia, United States, 30317|
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|United States, New York|
|Icahn School of Medicine at Mount Sinai|
|New York, New York, United States, 10029|
|United States, Ohio|
|University Hospitals Case Medical Center|
|Cleveland, Ohio, United States, 44106|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|United States, Pennsylvania|
|Drexel University College of Medicine|
|Philadelphia, Pennsylvania, United States, 19102|
|United States, Texas|
|Baylor College of Medicine: Department of Medicine|
|Houston, Texas, United States, 77030|
|Study Chair:||Nadine Rouphael, M.D.||Emory University|